Cook launches esophageal balloon; MagForce snags ex-Fresenius CEO;

 @FierceMedDev: Editor's Corner: Germany's Epigenomics is betting its future on an early-detection colon cancer Dx. Feature | Follow @FierceMedDev

 @DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. Yesterday's story | Follow @DamianFierce

> Cook Medical is launching its Hercules esophageal balloon to treat patients with gastrointestinal strictures. News

> Germany's MagForce has appointed former Fresenius CEO Ben Lipps to be the company's next chief executive. Story

> Life Technologies ($LIFE) has licensed out its Invivofectamine technology to a Chinese drugmaker to develop siRNA treatments. More

> Castle Biosciences has launched DecisionDx-EC, a diagnostic designed to determine whether esophageal cancer patients will respond to chemoradiation therapy. Release

> Beckman Coulter won FDA clearance for a new myocardial infarction diagnostic test. More

> ArtVentive Medical won a CE mark for its self-expanding catheter. Article

> Becton Dickinson's ($BDX) growing bioscience unit launched a new cell analyzer, marketing the BD LSRFortessa X-20 as more compact than its competitors. Item

Biotech News

 @FierceBiotech: Join what is probably one of the fastest-growing LinkedIn groups in biotech, & learn the meaning of life... sciences. Join now | Follow @FierceBiotech

 @JohnCFierce: Man, oh man. Bluebird IPO busts out, raises $101M as biotech offerings turn red hot - $BLUE up 50%. News | Follow @JohnCFierce

 @RyanMFierce: W/ $BLUE out, DMD drug developer Prosensa moves up in the biotech IPO queue, sets terms for $60M deal: More | Follow @RyanMFierce

 @EmilyMFierce: This week's issue of FierceBiotechResearch is out: Alzheimer's drug restores links in brain and more: This week's news | Follow @EmilyMFierce

> Sarepta shares spike on upbeat results from DMD extension study. News

> NIH backs pharma giants and academics' projects to revive R&D castoffs. Article

> Analysis: AMA decision on obesity will boost drug R&D in a troubled field. Editor's corner

> Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround. Story

Pharma News

 @FiercePharma: More Novo Nordisk bad news: Loses Prandin patent fight in U.S. Circuit court, $200m sales at risk. Report | Follow @FiercePharma

 @EricPFierce: U.K. gets nervous on looming deadline for API certifications, outlines contingency plan. Yesterday's report | Follow @EricPFierce

> Biogen's impressive Tecfidera launch hits reimbursement, supply snags. Article

> Onglyza fails outcomes trial in a $1B hit for Bristol-Myers, AstraZeneca. Story

> Use prescription meds properly, save $200 billion a year. Report

Drug Delivery News

 @MichaelGFierce: Self-propelled, spinning 'nano-necklaces' could pinpoint drug delivery. More | Follow @MichaelGFierce

> BD, JDRF partner to join artificial pancreas race. More

> Capsugel launches Lipidex platform for greater oral stability, potency. Item

> Teva grabs MicroDose respiratory biz with inhaled delivery platform. Article

> Drug-carrying 'nanovolcanoes' make precise delivery structures. Story